Overview Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects Status: Active, not recruiting Trial end date: 2023-06-30 Target enrollment: Participant gender: Summary This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants. Phase: Phase 1 Details Lead Sponsor: Daiichi Sankyo Co., Ltd.